Sale Of Ayurvedic Medicine For Joint Pain Put On Hold

Jammu: In the wake of a complaint received by the office of Drugs and Food Control Organization of J&K regarding an ayurvedic medicine, its sale has been put on hold in the UT till the verification of components used in it.

As per a letter by the office of Deputy Controller, Drugs and Food Control Organization, the available stock of ‘Batnashak Batika’ used for pain in joints has been put on hold till the report of analysis of samples is received.

The drug control authorities took action and lifted the samples of the medicine after social activist Sukesh Khajuria observed that the effect of the ayurvedic medicine was instant, which is contrary to the conventional understanding that these herbal medicines facilitate gradual healing and recovery.

“Pursuant to the communication by Sukesh Khajuria, where he requested for testing of ayurvedic propriety medicine ‘Batnashak Batika’. In this context a team of Drug Control Officers was constituted to investigate the matter,” the letter stated.

The team lifted the samples for analysis with respect to presence of steroids, as alleged by Khajuria. The samples were forwarded to the Indian Institute of Integrative Medicine (IIIM).

Khajuria said the ayurvedic medicine is increasingly being utilised for treatment of joint pains, particularly in patients who suffered from Chikungunya disease.

“Given the remarkable and expeditious healing attributed to this ayurvedic medicine, I harbour reservations regarding its composition,” Khajuria said.

Khajuria, in a letter to the drug controller, urged that the quality of drugs is beyond the understanding of common man. “It’s the responsibility of the department to ensure the availability of quality drugs to the public and the market is free from counterfeit, spurious and substandard drugs” he stated.

The social activist also shot off a letter to the Union Minister and other central and union territory officials pointing towards the dangers of sale of such drugs and medicines seeking chemical examinations of these medicines at the earliest.

Related Posts

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

NEW DELHI: Medical technology innovation is entering a new phase, with advanced cardiac implants, incisionless brain surgery, blood-based cancer screening, smart insulin delivery and real-time kidney-function monitoring among the technologies…

Three arrested after liquor bottles found at pharma firm

Patna: Three people were arrested and sent to jail after a large quantity of liquor bottles was found at Cellulas Pharma Private Limited in Kankarbagh during a raid by the…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

Three arrested after liquor bottles found at pharma firm

Three arrested after liquor bottles found at pharma firm

NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources

Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources